Research programme: anti-fibrotic agents - Pfizer

Drug Profile

Research programme: anti-fibrotic agents - Pfizer

Alternative Names: UK-383,367; UK-421,045

Latest Information Update: 05 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Hydroxamic acids; Oxadiazoles; Sulfonamides
  • Mechanism of Action Bone morphogenetic protein receptor type I antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Scars

Most Recent Events

  • 05 Aug 2009 This programme is in active development
  • 28 Aug 2007 Preclinical data added to the pharmacokinetics and Skin Disorders pharmacodynamics sections
  • 02 Sep 2004 Preclinical trials in Scars in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top